Adial Pharmaceuticals Announces Database Lock in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use DisorderGlobeNewsWire • 09/19/24
Adial Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceGlobeNewsWire • 09/04/24
Adial Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business UpdateGlobeNewsWire • 08/14/24
Adial Pharmaceuticals Announces Last Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use DisorderGlobeNewsWire • 08/07/24
Adial Pharmaceuticals Files New Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to 2044GlobeNewsWire • 07/31/24
Adial Pharmaceuticals Advances to Second Cohort in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use DisorderGlobeNewsWire • 07/23/24
Adial Pharmaceuticals Announces Publication in Leading Peer-Reviewed Journal Supporting the Potential Efficacy of AD04 as a Precision Medicine for the Treatment of Alcohol Use DisorderGlobeNewsWire • 06/20/24
Adial Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business UpdateGlobeNewsWire • 05/15/24
Adial Pharmaceuticals Granted Key Patent from the United States Patent and Trademark OfficeGlobeNewsWire • 04/22/24
Adial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use DisorderGlobeNewsWire • 04/10/24
Adial Pharmaceuticals Reports 2023 Fiscal Year Financial Results and Provides Business UpdateGlobeNewsWire • 04/02/24
Adial Pharmaceuticals Announces Exercise of Warrants for $3.5 Million Gross ProceedsGlobeNewsWire • 03/02/24
Adial Pharmaceuticals Awarded New Patent from the United States Patent and Trademark OfficeGlobeNewsWire • 02/28/24
Adial Pharmaceuticals to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20Accesswire • 02/15/24
Adial Pharmaceuticals Awarded New Patent Notice of Allowance from the United States Patent and Trademark OfficeGlobeNewsWire • 02/13/24